Industry News
Biotechnology Industry News
Ventyx nabs a $152M upsized IPO to challenge BMS’ Zeposia—and a backer with intimate knowledge of its rival
Ventyx nabs a $152M upsized IPO to challenge BMS' Zeposia—and a backer with intimate knowledge of its rival badams Thu, 10/21/2021 - 09:00
VCs back Leucid to trial CAR-T twist in ovarian cancer patients
VCs back Leucid to trial CAR-T twist in ovarian cancer patients ntaylor Thu, 10/21/2021 - 08:09
Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDA
Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDA ntaylor Thu, 10/21/2021 - 06:12
FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo test
FDA slaps clinical hold on AstraZeneca cancer drug amid heart safety scare in combo test badams Wed, 10/20/2021 - 13:59
Chase, after selling last biotech to Allergan, gets cash to start pivotal trials in depression, Parkinson’s
Chase, after selling last biotech to Allergan, gets cash to start pivotal trials in depression, Parkinson's ntaylor Wed, 10/20/2021 - 08:43
Takeda crashes out of Wave discovery pact at cost of $23M
Takeda crashes out of Wave discovery pact at cost of $23M ntaylor Wed, 10/20/2021 - 07:51
Princeton and MIT gene-editing pioneers uncover clues for improving CRISPR and other tools
Princeton and MIT gene-editing pioneers uncover clues for improving CRISPR and other tools aliu Wed, 10/20/2021 - 06:20
Amid Amgen’s similar struggles, AstraZeneca slams the brakes on MCL-1 blood cancer drug
Amid Amgen's similar struggles, AstraZeneca slams the brakes on MCL-1 blood cancer drug badams Wed, 10/20/2021 - 06:11
Injured tumor cells activate immuno-oncology drugs to combat breast cancer and melanoma in mice
Injured tumor cells activate immuno-oncology drugs to combat breast cancer and melanoma in mice arlene.weintraub Tue, 10/19/2021 - 11:06
Dicerna narrows focus for kidney drug after mixed data, setting up head-to-head market battle with rival Alnylam
Dicerna narrows focus for kidney drug after mixed data, setting up head-to-head market battle with rival Alnylam badams Tue, 10/19/2021 - 08:57
Atea and Roche’s COVID-19 antiviral flunks phase 2, prompting switch that will delay pivotal data
Atea and Roche's COVID-19 antiviral flunks phase 2, prompting switch that will delay pivotal data ntaylor Tue, 10/19/2021 - 08:11
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug ntaylor Tue, 10/19/2021 - 07:33
Sofinnova bulks out VC shop with a hefty $548M as it zeroes in on early-stage European biotechs
Sofinnova bulks out VC shop with a hefty $548M as it zeroes in on early-stage European biotechs badams Tue, 10/19/2021 - 03:44
A new target in multiple myeloma? TAK1 blocker boosts chemo’s cancer-killing power in preclinical study
A new target in multiple myeloma? TAK1 blocker boosts chemo's cancer-killing power in preclinical study arlene.weintraub Mon, 10/18/2021 - 09:31
FDA rejects Omeros transplant drug over difficulties estimating its effect
FDA rejects Omeros transplant drug over difficulties estimating its effect ntaylor Mon, 10/18/2021 - 07:57
Biogen’s ALS drug has failed phase 3. Will FDA approve anyway?
Biogen's ALS drug has failed phase 3. Will FDA approve anyway? ntaylor Mon, 10/18/2021 - 05:13
Greenwood takes the top job at Kojin Therapeutics, leading an all-woman biotech C-suite
Greenwood takes the top job at Kojin Therapeutics, leading an all-woman biotech C-suite badams Fri, 10/15/2021 - 10:02
Inhalable anti-COVID-19 antibody from TFF and Augmenta tamps down viral load in hamsters
Inhalable anti-COVID-19 antibody from TFF and Augmenta tamps down viral load in hamsters arlene.weintraub Fri, 10/15/2021 - 08:26
AstraZeneca delivers rare win for treme in liver cancer, bouncing back from flops to beat Bayer’s Nexavar
AstraZeneca delivers rare win for treme in liver cancer, bouncing back from flops to beat Bayer's Nexavar ntaylor Fri, 10/15/2021 - 07:58
Chinese biopharma powerhouse continues charge into siRNA with Silence R&D pact
Chinese biopharma powerhouse continues charge into siRNA with Silence R&D pact ntaylor Fri, 10/15/2021 - 04:33